Eli Lilly Completes Acquisition of AtaiBeckley Inc.

Eli Lilly (LLY) announced that the acquisition of AtaiBeckley Inc. (ATAI) has been completed. The transaction, valued at approximately $3.8 billion, was announced on 11 September 2026 and was finalized the following day.

Transaction Details

  • Purchase price: $6.75 cash per share, representing an initial value of $2.8 billion.
  • Earn‑out provision: An additional payment of $1 billion may be paid if AtaiBeckley meets specified clinical, regulatory and commercial milestones.
  • Total potential value: $3.8 billion.
  • Closing date: The merger closed prior to the market open on 9 September 2026.

The completion of the deal enhances Eli Lilly’s neuroscience portfolio and expands its capabilities in the treatment of clinical depression and other mental‑health conditions. Eli Lilly has pursued a strategy of growth through acquisitions, having spent roughly $35 billion on corporate buyouts since 2020.

Corporate Action and Shareholder Impact

  • Shareholder vote: AtaiBeckley shareholders voted on the proposed merger on 8 September 2026.
  • Stock suspension: Following the after‑hours session on 8 September, the ATAI shares were halted and subsequently suspended effective 10 September 2026.
  • Shareholder compensation: Holders of AtaiBeckley shares received $6.75 USD and one non‑tradable contingent value right (CVR) per share.
  • Market status: The merger is listed as a mandatory event on the Mexican Stock Exchange (Bolsas y Mercados Españoles – BMV) and on Nasdaq in the United States.

Company Background

AtaiBeckley Inc. is a clinical‑stage biopharmaceutical company that focuses on both psychedelic and non‑psychedelic compounds for the development of disease‑modifying mental‑health treatments. The company is headquartered in Berlin, Germany, and is listed on the Frankfurt Stock Exchange under the ticker ATAI. Its 2026 closing share price was $7.35, with a 52‑week high of $7.45 and a 52‑week low of $3.265. The company’s market capitalization stood at approximately $2.73 billion.

The acquisition represents a significant expansion of Eli Lilly’s pipeline in mental‑health therapeutics, complementing its existing portfolio that spans oncology, diabetes, obesity, and Alzheimer’s disease.